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Over the past 20 years, the incidence of cutaneous malignant melanoma (CMM) has increased dramatically world-
wide. A positive family history of the disease is among the most established risk factors for CMM; it is estimated
that 10% of CMM cases result from an inherited predisposition. Although mutations in two genes, CDKN2A and
CDK4, have been shown to confer an increased risk of CMM, they account for only 20%–25% of families with
multiple cases of CMM. Therefore, to localize additional loci involved in melanoma susceptibility, we have per-
formed a genomewide scan for linkage in 49 Australian pedigrees containing at least three CMM cases, in which
CDKN2A and CDK4 involvement has been excluded. The highest two-point parametric LOD score (1.82; recom-
bination fraction [v] 0.2) was obtained at D1S2726, which maps to the short arm of chromosome 1 (1p22). A
parametric LOD score of 4.65 ( ) and a nonparametric LOD score of 4.19 were found at D1S2779 in ninevp 0
families selected for early age at onset. Additional typing yielded seven adjacent markers with LOD scores 13 in
this subset, with the highest parametric LOD score, 4.95 ( ) (nonparametric LOD score 5.37), at D1S2776.vp 0
Analysis of 33 additional multiplex families with CMM from several continents provided further evidence for
linkage to the 1p22 region, again strongest in families with the earliest mean age at diagnosis. A nonparametric
ordered sequential analysis was used, based on the average age at diagnosis in each family. The highest LOD score,
6.43, was obtained at D1S2779 and occurred when the 15 families with the earliest ages at onset were included.
These data provide significant evidence of a novel susceptibility gene for CMM located within chromosome band
1p22.
Introduction
Cutaneous malignant melanoma (CMM) represents a
significant public health burden in all populations of
European origin. In the United States, for example,
CMM incidence has increased at a rate greater than that
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of any other cancer type (477% increase in incidence
between 1950 and 1998, based on Surveillance, Epi-
demiology, and End Results [SEER] data) (Ries et al.
2003). Incidence rates vary by more than an order of
magnitude even in susceptible populations, with lifetime
risk of CMM ranging from 0.2% in southern Europe
to 1% in the United States and Scandinavia and an av-
erage of 4% in Australia. According to SEER data, the
5-year survival rate for CMM decreases dramatically
(from 96% to 12%) in more advanced stages of disease
(Ries et al. 2003). It is hoped that further characteri-
zation of the genetic factors contributing to an elevated
risk of developing CMM will form a basis for under-
standing which individuals in susceptible populations
are most at risk, how that risk can be modified, and how
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Table 1
Characteristics of Families with Melanoma
Sample Site Phase
No. of
Families
per Site
Average No.
of Affected
Individuals
per Family
(Range)
Average No.
of Affected
Individuals
Typed per
Family
(Range)
Average Age
at Diagnosis
in Years per
Family (Range)
Queensland Institute of Medical Research, Brisbane, Australia 1 27 4.5 (3–8) 3.9 (3–7) 45.5 (29.7–76)
Westmead Institute for Cancer Research, Sydney, Australia 1 22 4.1 (3–7) 3.6 (3–6) 43.8 (24–65)
Queensland Institute of Medical Research, Brisbane, Australia 2 9 4.2 (3–8) 3.2 (3–4) 46.6 (30–58.6)
Westmead Institute for Cancer Research, Sydney, Australia 2 15 3.7(3–8) 3.4 (3–7) 44.3 (28.8–62.7)
Genetic Epidemiology Branch, National Cancer Institute, Bethesda, U.S.A. 2 2 4.5 (3–6) 3.5 (3–4) 41.9 (38.8–45)
Leiden University Medical Center, Leiden, The Netherlands 2 2 5.5 (5–6) 5.5 (5–6) 43.9 (39.3–48.4)
Cancer Research UK, Leeds, U.K. 2 2 3 3 44.3 (27.3–61.3)
Institut Gustave Roussy, Villejuif, France 2 1 5 4 41.2
University Hospital, Lund, Sweden 2 1 5 4 54.6
Karolinska Hospital, Stockholm, Sweden 2 1 3 3 49
that knowledge would allow targeted surveillance and
recognition of disease at early stages, when treatment
strategies are maximally beneficial.
The etiology of CMM is complex, involving both
heterogeneous genetic and environmental components.
The CDKN2A locus (MIM 600160) accounts for sus-
ceptibility in ∼25% of all kindreds with familial CMM
(Goldstein et al. 2000), whereas mutations in the CDK4
(MIM 123829) gene have, to date, been documented in
only three CMM-prone families (Zuo et al. 1996; Soufir
et al. 1998). The average lifetime risk conferred by
CDKN2A mutations is ∼70% in multiple-case families
but shows significant variation between regions (Bishop
et al. 2002). In contrast to these high-penetrance mu-
tations, variants of the melanocortin receptor 1 gene
(MC1R) have proven to be low-penetrance or medium-
risk susceptibility alleles for CMM (Palmer et al. 2000).
These MC1R (MIM 155555) variants also act as mod-
ifier alleles, increasing the penetrance of mutations in
CDKN2A (Box et al. 2001; van der Velden et al. 2001).
Clearly, additional CMM predisposition genes are likely
to exist.
Material and Methods
Families
Ascertainment and clinical evaluation of the 49 Aus-
tralian pedigrees with familial CMM included in our ge-
nomewide scan (phase 1) are described elsewhere (Kefford
et al. 1991; Nancarrow et al. 1992b). In an effort to
maximize the chance of identifying a novel high-risk sus-
ceptibility gene, we restricted inclusion in our study to
pedigrees that were mutation negative for both CDKN2A
and CDK4, by SSCP and/or direct sequencing, and con-
tained at least three CMM cases with DNA from blood
available for genotyping. In addition, any pedigree show-
ing evidence of haplotype sharing in the 9p21-p22 re-
gion, where CDKN2A is located, was also excluded, to
minimize inclusion of families with undetected muta-
tions within the CDKN2A gene or outside the coding
region. Several noncoding mutations in CDKN2A have
been identified (Liu et al. 1999; Harland et al. 2001).
In total, our genomewide scan was conducted in 49 Aus-
tralian families (phase 1, table 1). Each family was highly
loaded with CMM cases (average number of affected
individuals 4.3, range 3–8). Although we required that
each family have at least three affected individuals, 37%
of the families (18/49) had more than five affected in-
dividuals. There was no evidence of an excess of pan-
creatic cancer in these families, as has been previously
reported in some CDKN2A mutation–positive families
(Goldstein et al. 1995; Borg et al. 2000; Vasen et al.
2000); however, three families contained cases of both
cutaneous and ocular melanoma. Pedigrees included in
the second phase analyses (phase 2, table 1) were iden-
tified and collected in Australia, the United States, the
United Kingdom, France, Sweden, and The Netherlands,
by members of the Melanoma Genetics Consortium.
More details about the families can be found elsewhere
(Bergman et al. 1992; Hussussian et al. 1994; Gruis et
al. 1995; Platz et al. 1997; Soufir et al. 1998; Hashemi
et al. 1999; Newton Bishop et al. 1999; Bishop et al.
2000; Borg et al. 2000; Goldstein et al. 2000; Harland
et al. 2000). The goal of the Melanoma Genetics Con-
sortium, established in 1997, is to investigate factors
related to the inheritance of an increased risk of mela-
noma (Kefford et al. 1999; Bishop et al. 2002). Mela-
noma cases were verified as thoroughly as possible from
cancer registries, pathology reports, or clinical records.
Genotyping
Genomic DNA was prepared from blood samples
through use of standard techniques. DNA samples were
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Table 2
Power To Detect Linkage In 49 Genomewide Scan Pedigrees:
Parametric Analysis (LOD)
PROPORTION
OF FAMILIES
WITH
LINKAGE
LOD SCORE % WITH LOD SCORE
Mean Maximum 1 2 3
0% 21.25 6.47 .0 .0 .0
25% 15.45 4.49 .1 .1 .1
50% 7.47 9.54 12.6 8.7 6.9
75% 2.05 17.00 65.0 61.3 55.7
100% 13.58 20.94 100.0 99.8 99.8
genotyped using 414 STR markers with an average in-
termarker spacing of 10 cM and an average heterozy-
gosity of 80%. PCRs, using fluorescently labeled prim-
ers, were set up using a TECAN Genesis 200 robot. All
PCRs were performed in a 15-ml volume containing 20
ng of genomic DNA, 0.33 mM each primer, 0.25 mM
each dNTP, 2.5 mM MgCl2, 10 mM Tris-HCl, 50 mM
KCl, and 0.5 U Taq polymerase. PCR amplification was
performed using the GeneAmp 9600 or 9700 thermo-
cyclers (Applied Biosystems). PCR cycling conditions
were as follows: 95C for 12 min, followed by 10 cycles
of 94C for 15 s, 55C for 15 s, 72C for 30 s, and 20
cycles of 89C for 15 s, 55C for 15 s, and 72C for 30
s, with a final extension of 72C for 10 min. Depending
on the PCR yield, 5–15 ml of product was combined
with those of as many as 20 other markers of appro-
priate size and fluorescent label. PCR products were sep-
arated using the ABI 377/3100 DNA sequencer, allowing
multiple fluorescently labeled markers to be run in a
single lane. The ROX 400 size standard was run as an
internal size standard. Allele sizing was calculated using
the local southern algorithm available in the GENE-
SCAN software program (Applied Biosystems). Allele
calling and binning were performed using GENOTYPER
software (Applied Biosystems). All genotyping was per-
formed with the inclusion of a CEPH control individual
(1347–02), for quality control purposes.
Statistical Analyses
Simulations were performed using the SLINK and
GENEHUNTER programs. Power analyses were per-
formed under the assumption of a dominant affecteds-
only model with a gene frequency of 0.003 and a rate of
sporadic disease in nongene carriers that ranged between
0% and 4%, increasing with age. Individuals with ocular
or cutaneous melanoma were coded as “affected,” and
all other individuals were coded as “unknown.” A linked
(i.e., 5 cM from the trait) marker with six equally frequent
alleles was simulated using the SLINK program. Two-
point parametric LOD scores were calculated using the
GENEHUNTER program. The results in table 2 are based
on 1,000 replicates for each parameter set.
The quality of our data was checked in several ways.
First, genotyping data were checked for Mendelian in-
consistency through use of both the GAS and Pedcheck
programs. Any marker violating Mendelian transmis-
sion was double checked in the laboratory. Ambiguous
marker genotypes were deleted to reduce further prob-
lems in statistical analysis. Second, genotype data integ-
rity was further checked using the CRIMAP program.
The marker order and distances were estimated from the
data and were compared to publicly available genetic
and physical maps. Finally, biological kinship was also
examined, using the RelCheck computer program. The
RelCheck program used the genotypic information of
autosomal markers in this genome scan to calculate the
most likely relationship of a putative relative pair. Five
relationships were considered: MZ twins, parent/off-
spring, full sibs, half sibs, and unrelated individuals. Al-
lele frequencies were estimated from all genotyped in-
dividuals using the Gconvert program (David Duffy’s
QIMR Homepage).
Parametric analyses were performed using the domi-
nant genetic model derived using data from the Austra-
lian cancer registries and age-specific penetrances esti-
mated from pedigree data (Nancarrow et al. 1992b).
This model specifies a disease allele frequency of 0.003
and eight liability classes, with penetrances of 0.005,
0.13, 0.31, 0.52, 0.62, 0.7, 0.77, and 0.8 for ages 0–15
years, 16–25 years, 26–35 years, 36–45 years, 46–55
years, 56–65 years, 66–75 years, and 175 years, re-
spectively, for disease gene carriers; and phenocopy rates
of 0, 0.001, 0.005, 0.011, 0.018, 0.026, 0.032, and 0.04
for the same age groups for noncarriers. To reduce the
impact of incomplete penetrance, all unaffected individ-
uals were coded as “unknown” in our analyses. Two-
point parametric analyses were performed using the
FASTLINK program (Lathrop et al. 1984).
Nonparametric analyses were also performed using
the pseudomarker approach, which approximates a
model-free affected relative pair analysis but maintains
an important property of LOD score analysis: pedigree
correlations between all relatives are considered jointly,
and the pedigree is not broken into a set of all possible
relative pairs (Go¨ring and Terwilliger 2000). We also
assume that the mode of inheritance is dominant in this
nonparametric analysis.
The predivided samples test (Morton 1956) was used
to test for heterogeneity between the nine families with
early onset and the remaining families in the phase 1
data. Ordered sequential analysis was performed on the
basis of average age at diagnosis in each family. In this
analysis, using the 46 markers spanning the most prom-
ising region, we determined the maximum two-point
nonparametric LOD score in all families and then re-
moved the family with the highest mean age at diagnosis
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Figure 1 A, Parametric two-point LOD scores for the genome-
wide scan. Affected and unaffected individuals in 49 pedigrees with
melanoma were genotyped at 414 loci throughout the genome. Max-
imum two-point LOD scores were calculated and the results plotted
as a function of order along the chromosome. B, Nonparametric two-
point LOD scores for the genomewide scan for the same 49 pedigrees
with melanoma. C, Maximum two-point parametric LOD scores for
the genomewide scan for nine families with the earliest age at onset.
and repeated the analyses. Multipoint linkage analyses
were performed using both parametric and nonpara-
metric methods, implemented by the computer program
GENEHUNTER-PLUS (Kruglyak et al. 1996; Kong and
Cox 1997). For the parametric analyses, the same au-
tosomal dominant model used in the two-point analyses
(indicated above) was assumed. Linkage in the presence
of heterogeneity was assessed by use of Smith’s admix-
ture test for heterogeneity.
Results
Simulations were performed to evaluate the empirical
type 1 error and the estimated power to detect linkage
under the assumption that certain percentages of families
(0%, 25%, 50%, 75%, or 100%) show linkage to a
given locus (table 2) (Ott 1989; Weeks et al. 1990).
When the case in which none of the families was linked
is considered, the family set is robust against type 1
errors: none of the simulated parametric results (out of
1,000 replicates) showed a LOD score 11.
For the parametric analyses of genotype data, we used
an affecteds-only model that assumed a dominant mode
of transmission for the trait and a gene frequency of
0.003. The use of an affecteds-only model reduces the
effect of incomplete penetrance by coding all unaffected
individuals as “unknown.” The model also allowed for
an age-dependent phenocopy rate, appropriate for Aus-
tralian populations, that ranged from 0% to 4% (Nan-
carrow et al. 1992b). Plots of the two-point parametric
and nonparametric LOD scores for the genomewide
scan are shown in figure 1A and 1B. The highest LOD
score observed was 1.82 (recombination fraction [v]
0.2) at marker D1S2726, which maps to the short arm
of chromosome 1 (1p22). The nonparametric LOD
score at D1S2726 was 2.06. On the basis of our sim-
ulations, the probability of obtaining a parametric LOD
score this high in the absence of linkage was !.001 (table
2). In addition to chromosome 1p, several other regions
showed LOD scores 11.0 in either parametric or non-
parametric analyses, including regions on chromosomes
4, 7, 14, and 18 (fig. 1A and 1B). We have focused our
follow-up efforts on chromosome 1, however, since it
was the only chromosome for which three closely lo-
cated markers, D1S207, D1S2779, and D1S2726, all
gave LOD scores 11.0.
To minimize genetic heterogeneity, we performed sub-
set analyses based on the mean age at diagnosis within
each family. To empirically define a cutoff point, we
plotted the age at diagnosis from all 212 affected in-
dividuals from all 49 families (fig. 2). The distribution
of age at diagnosis suggested a mixture of two or three
underlying normal distributions with a clear peak at age
35 years. When we assigned this age as a cutoff point,
nine families with a mean age at diagnosis 35 years
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Figure 2 Age at onset for 212 affected individuals from the 49 families with melanoma included in genomewide scan for linkage in
phase 1.
were stratified as “early onset” for the subset analyses.
Parametric linkage analysis of our genomewide scan
data in these nine families with early-onset disease
revealed six consecutive markers on chromosome 1
(1p22) with two-point LOD scores 11.0; the highest
LOD score was 4.65 at marker D1S2779 ( ) (fig.vp 0
1C). The two-point LOD score at D1S2779 ( ) invp 0
the remaining 40 families without early onset was
13.95. Furthermore, in the same group of 40 families
without early onset, the maximum two-point LOD
score at this marker was 0.06 ( ) (table 3). Thevp 0.4
predivided samples test for heterogeneity between these
two classes of families was highly significant ( 2x p
; 1 df; ). Nonparametric analyses also12.88 P ! .001
produced similar results; seven consecutive markers had
nonparametric LOD scores 11.0, with the highest non-
parametric LOD score, 4.19, at D1S2779.
To further validate our results and narrow the region
of interest, 43 additional markers covering ∼30 cM
(flanking marker D1S2779) in the 1p22 region were
typed (table 3). These markers provided further evi-
dence for linkage. The overall maximum two-point
parametric LOD score increased to 2.58 ( ) atvp 0.15
marker D1S2776. In the families with early onset, there
were 3 markers with two-point parametric LOD scores
4 and 12 markers with LOD scores 13. The highest
two-point parametric LOD score increased to 4.95
( ) at D1S2776. The results from nonparametricvp 0
analyses were similar: one marker with a LOD score
15.0, four markers with LOD scores 14, and 13 markers
with LOD scores 13, with the highest two-point non-
parametric LOD score, 5.37, at D1S2776.
In the second phase of evaluating the evidence for
linkage in this region, we genotyped 63 additional fam-
ilies, through use of our dense panel of 46 markers from
1p22. Of these families, 33 met our original criteria for
inclusion into the study—that is, they had DNA avail-
able from blood for at least three individuals affected
with CMM, they were both CDKN2A- and CDK4-
mutation negative, and, furthermore, they showed no
common haplotype in the 9p21-p22 region among af-
fected individuals (i.e., they showed no evidence of link-
age to 9p). The remaining 30 families did not meet our
original criteria for inclusion into the study, because the
three affected individuals showed evidence of haplotype
sharing in the 9p21-p22 region (i.e., they showed evi-
dence of linkage to 9p). Since these families might have
undetected CDKN2A mutations, their evidence for link-
age was examined independently. All families came
from the Melanoma Genetics Consortium and repre-
sented eight different sites in Australia, Europe, and the
United States (table 1). Our analyses focused on the 82
families that met our original criteria (phase 1 [np
] and phase 2 [ ]) (table 1). Given that these49 np 33
families were ascertained from countries reporting var-
ying melanoma incidences and penetrances (Bishop et
al. 2002), our subsequent analyses were performed us-
ing nonparametric methods only.
Inclusion of the additional 33 phase 2 families in-
creased our evidence for linkage in the 1p22 region. With-
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Figure 3 Ordered sequential analysis, based on the mean age at diagnosis in each family. Overall maximum two-point nonparametric
LOD scores for chromosome 1 markers for families with the lowest mean age at onset to the highest (left to right).
out stratification by average age at diagnosis, the max-
imum two-point nonparametric LOD score increased to
2.97 at marker AA205XD5 (table 3). Furthermore, six
markers in the region showed overall two-point non-
parametric LOD scores 12.0, and eight families showed
individual family LOD scores 11.0. Again, we were in-
terested in looking at the evidence for linkage in the fam-
ilies with early onset but were reluctant to use a single
age cutoff, given the differing age-dependent risks of
CMM in mutation carriers in the various countries from
which our families originated. Ordered sequential anal-
ysis was therefore performed, on the basis of the average
age at diagnosis in each family. In this analysis, we looked
at the evidence for linkage in all families, then removed
the family with the highest mean age at diagnosis and
repeated the analyses. Figure 3 shows the evidence for
linkage in the families with the lowest mean age at di-
agnosis to the highest (left to right). In these nonpara-
metric analyses, the highest two-point LOD score, 6.43,
was obtained at D1S2779 and occurred when the 15
families with earliest onset were included for analysis (fig.
3). The oldest average age at diagnosis for this empirically
defined subset of families was 35.7 years, very similar to
the cutoff used in the 49 phase 1 Australian kindreds
(35 years). When defined in this way, the proportion
of families with linkage to 1p22 is 18% of the initial 49
families ( ; all from Australia), as well as 18% ofnp 9
the total cohort of 82 families ( ; 14/15 from Aus-np 15
tralia). We attempted to evaluate the empirical signifi-
cance of these results in two ways. First, we evaluated
the empirical significance of this subset of 15 families by
resampling 15 families randomly from the set of 82 fam-
ilies and recalculating the total LOD score on this subset.
This process was repeated 1,000,000 times. Only five
replicates gave LOD scores greater than or equal to our
observed value of 6.43, resulting in an empirical signif-
icance level of .000005. This empirical P value is equal
to an empirical LOD score of 4.2. Second, we performed
100,000 replicates, simulating an unlinked marker in
these 15 families with early onset. No replicate gave a
LOD score that was equal to the observed value of 6.43.
In fact, only 10 replicates out of 100,000 gave LOD
scores 12, of which only 2 were 13 (maximum LOD
score 3.04).
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Results from parametric and nonparametric multi-
point analyses were consistent with the two-point re-
sults. Given inconsistencies in the order of markers be-
tween the draft human genome sequence and published
genetic maps of this region, we performed multipoint
analyses that included only the 33 (of 46) markers in
this region that could be unambiguously ordered. (A
YAC-based physical map has been developed that spans
the entire candidate region with one small gap, through
use of Whitehead Institute’s YAC database; STS content
mapping of these YACs with primers for the genetic
markers has provided us with a precise order of 33
markers.) In the complete family set ( ), the high-np 82
est parametric multipoint LOD score allowing for
heterogeneity was 2.36, between loci D1S430 and
D1S2862. The estimated proportion of families with
linkage was 17%, which is consistent with our estimate
using the ordered sequential analysis (18%). HLOD
scores were 11.0 across an ∼16-cM region. In the 15
families with early onset defined by the ordered se-
quential analysis, the maximum multipoint LOD score
allowing for heterogeneity was 4.83, between markers
D1S435 and D1S188. In this analysis, the estimated
proportion of families linked was 65%.
To define the region of interest more precisely, we
looked for potential recombinants in the families with
linkage—that is, the 15 families with early onset con-
tributing to the ordered sequential analysis peak. Several
informative recombination events were noted, and they
delimited the region to D1S430 on the telomeric side
and D1S2664 on the centromeric side, an interval of
∼20 cM. There are several good candidate genes within
this region—namely, the TGFBR3 and CDC7 genes. We
are currently working to determine whether either gene
is involved in melanoma susceptibility.
Discussion
We report the results from the first complete genome-
wide scan for linkage for melanoma susceptibility. Our
goal was to localize novel genes involved in melanoma
susceptibility. We restricted inclusion into our study to
highly loaded melanoma pedigrees, which were muta-
tion negative for both CDKN2A and CDK4. Further-
more, we excluded any family with evidence of haplo-
type sharing in the 9p21-22 region where CDKN2A is
located. This strategy may prove conservative, but it
helped to minimize the possibility of including families
with undetected CDKN2A involvement. Genetic hetero-
geneity is a significant factor contributing to the diffi-
culty of mapping genes involved in complex traits; there-
fore, our strict inclusion criteria, as well as subset
analyses, may have improved the power of our study.
In the first phase of our study, we performed both
parametric and nonparametric analyses. Both methods
provided evidence for linkage between a melanoma sus-
ceptibility locus and markers on chromosome 1p. The
highest parametric LOD score observed was 1.82
( ), at marker D1S2726, which maps to the shortvp 0.2
arm of chromosome 1 (1p22). The highest nonpara-
metric LOD score at D1S2726 was 2.06. On the basis
of our simulations, the probability of obtaining a par-
ametric LOD score this high by chance alone was small
(!.001).
In our parametric analyses, we employed two strat-
egies, which were also aimed at increasing the power
of our study. First, using an affecteds-only model re-
duces the effect of incomplete penetrance by coding all
unaffected individuals as “unknown.” Our model still
allowed for phenocopies in non–gene carriers. The al-
lowance for sporadic cases of melanoma in the model
is critical, since sun exposure is known to be a significant
environmental risk factor for CMM. Ideally, we would
have reliable sun-exposure data for each individual in
the study, thus allowing its incorporation into the model
as a covariate. However, since these data are currently
unavailable, we attempted to allow for the effect of this
unmeasured environmental risk factor by including
nongenetic cases in our model. Second, the utilization
of liability classes can maximize power in the investi-
gation of complex traits, which often exhibit reduced
penetrance and phenocopies. Specifically, in our anal-
yses, liability classes allowed us to incorporate the ob-
served increase in sporadic rate with increasing age into
our model. Thus, with the incorporation of liability clas-
ses defined by age, we maximized linkage information
from younger affected individuals who are more likely
to be gene carriers.
Since parametric analyses are model dependent and
it is well known that misspecification of the disease
model (especially misspecification of a trait’s degree of
dominance) can lead to a decrease in power as well as
a biased estimate of v (Clerget-Darpoux et al. 1986),
we also used nonparametric analyses to further examine
linkage data in this region. Because the families in the
present study were identified and collected from pop-
ulations that report varying melanoma incidences and
penetrances (Bishop et al. 2002), the second phase of
analyses was performed using nonparametric methods
only. In contrast to parametric methods, in which in-
formation regarding the genetic model of the trait is
essential, the nonparametric methods do not require
that details regarding the underlying genetic model of
the trait be specified. Without stratification by average
age at diagnosis, the maximum two-point nonpara-
metric LOD score was 2.97 at marker AA205XD5. It
should be noted that this region on chromosome 1
(1p22) is genetically unlinked (150 cM away) to the
1p36 region where linkage to CMM has previously been
reported (MIM 155600) (Bale et al. 1989; Goldstein et
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al. 1993), though not confirmed, in other cohorts (van
Haeringen et al. 1989; Cannon-Albright et al. 1990;
Kefford et al. 1991; Nancarrow et al. 1992a).
The previous identification of two genes, CDKN2A
and CDK4, that independently confer susceptibility to
CMM suggests that genetic heterogeneity is likely to be
a complicating variable in the gene mapping of CMM
risk alleles (despite the analysis method). We therefore
explored subset analysis, using age at diagnosis as a
criterion. This strategy has been critical to the successful
mapping of other cancer genes (Hall et al. 1990; Smith
et al. 1996). Furthermore, examining the evidence of
linkage in the families with early onset is consistent with
epidemiological data, which suggests that, like other
hereditary cancers, familial melanomas develop at an
earlier age than nonfamilial melanomas. By using an
ordered sequential analysis, we avoided using a single
age at diagnosis to define families with “early onset.”
Figure 3 clearly shows that the evidence for linkage to
this 1p locus is strongest in the families with earlier
onset. The highest nonparametric LOD score, 6.43, was
obtained at D1S2779 and occurred when the 15 families
with earliest onset were included. On the basis of ex-
tensive simulations performed to evaluate the empirical
significance of these results, it is highly unlikely that
these results would have occurred by chance. Future
analyses will include stratification based on other phe-
notypic criteria, such as segregation of both ocular and
cutaneous melanoma.
Although the significant evidence of linkage to 1p
obtained in this study was identified in families showing
no evidence of linkage to 9p, we were interested in look-
ing at the evidence for linkage in the 30 families with
linkage to 9p. Since these families might have unde-
tected CDKN2A mutations, their evidence for linkage
was examined independently. As expected, examining
the family-by-family two-point LOD scores suggests
that this 1p locus is not significant in families with ev-
idence of linkage to 9p. Of the 46 1p22 markers typed,
45 had negative LOD scores out to v values of .4 (data
not shown).
Our current candidate interval spans a region of ∼15
Mb across chromosomal bands 1p31.1 to 1p21.3 and
contains 60 known genes, several partial transcripts,
and several predicted transcripts. Identification of the
susceptibility gene by the positional candidate cloning
approach will most likely require further narrowing of
the candidate region. Availability of the draft human
genome sequence will provide a major resource to iden-
tify new markers for this purpose. However, identifi-
cation of new kindreds with early age at diagnosis for
melanoma and subsequent genotyping for markers from
the candidate region may be more helpful in pinpointing
the precise localization of the susceptibility gene within
the candidate interval. To this end, phase 3 of our study
is focused on identification of new families with mela-
noma that again have had CDKN2A and CDK4 in-
volvement excluded by both mutation detection and
linkage analysis.
Within the 15 families with early onset contributing
to the ordered sequential analysis peak, haplotypes were
constructed using the 46 markers typed on 1p. Segre-
gation of the haplotypes was determined and recom-
binants were considered useful only in those families in
which all affected individuals carried the same haplo-
type for at least part of the region typed on 1p. Recom-
binants were detected in seven individuals. Pooling this
information across families allowed us to narrow our
region of interest to a 20-cM region between markers
D1S430 and D1S2664. However, the potential com-
plexity of the underlying genetic model of melanoma
should generate caution. Specifically, an affected indi-
vidual does not necessarily share the susceptibility allele
and might instead represent a sporadic case of mela-
noma. However, in our families, the recombinant in-
dividuals ranged in age from 24 to 36 years and are
thus likely to be gene carriers.
Given that both CDKN2A and CDK4 are known to
function in cell-cycle regulation, two genes within our
candidate region—transforming growth factor b recep-
tor 3 (TGFBR3) and cell division cycle 7–related ki-
nase (CDC7)—could be considered as candidates for
contributing to melanoma susceptibility. Both genes
map close to the markers with the peak LOD scores
(D1S2776 and D1S2779) and play important biological
roles in cell differentiation and cell cycle progression.
TGFBR3 plays an essential role in the TGF-b signaling
pathway (Brown et al. 1999), which, if disrupted, can
lead to rapid cell growth (Derynck et al. 2001). CDC7
protein kinase is involved in regulation of DNA repli-
cation (Sato et al. 1997) and is, therefore, essential in
maintaining the cell cycle.
In summary, we have localized a novel CMM sus-
ceptibility gene to 1p22, through use of a cohort of 82
familial melanoma kindreds in which CDKN2A and
CDK4 involvement has been excluded. Evidence for
linkage is strongest in the ∼20% of families with the
earliest age at diagnosis. Ordered sequential nonpara-
metric analyses indicated that the highest two-point
LOD score was 6.43, at marker D1S2779; results from
multipoint analyses were consistent with the two-point
results. These data provide significant evidence of a
novel CMM susceptibility gene located within chro-
mosome band 1p22. By analogy to other hereditary
cancers, the identification of genes that confer an in-
herited genetic predisposition to CMM may provide in-
sights into the etiology of all melanomas. Furthermore,
characterization of the molecular basis of these genetic
Gillanders et al.: Localization of a Novel Melanoma Locus 311
effects will enhance melanoma risk assessment and may
ultimately lead to interventions that can reduce mela-
noma-associated morbidity and mortality.
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